The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that h…

Breast CancerBreast Cancer FemaleMetastatic Triple-Negative Breast Carcinoma+4 more

~Estimated

~$10 – $7,500

Nancy Lin, MDNCT06176261

Phase 2

A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)

This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study d…

Invasive Breast CancerTriple Negative Breast CancerER-Negative Breast Cancer+2 more

~Estimated

~$10 – $6,250

Massachusetts General HospitalNCT04230109